PONS image enhancement for drug development

Unlocking New Ultrasound Insights for Drug Development

Ultrasound is a safe, accessible imaging modality poised to play an expanded role in pharma research and trials. But standard ultrasound lacks the resolution and quantification capacity needed for assessing detailed tissue characterization, treatment response and side effect patterns.

This is now possible with PONS - our AI-enhanced ultrasound software unveiling tissue insights invisible on conventional devices. By boosting image clarity, accuracy and data extraction from basic ultrasound, PONS can unlock new biomarkers tracking disease progression, drug impact and adverse effects over time – all through repeat non-invasive scans.

Our technology opens the door to nuanced ultrasound imaging biomarkers that are personalized, low-cost, and easily embedded into care workflows. This can transform pharmacotherapy across oncology, cardiology, immunology and other therapeutic areas - enabling trials powered by robust new ultrasound outputs. Backed by our rapidly growing imaging dataset, PONS promises to shake up the role of ultrasound in drug development going forward.